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Viruses with completely or predominantly negative-
sense RNA genomes span six viral families: the nonseg-
mented Rhabdoviridae, Paramyxoviridae, and Filoviridae
and the segmented Orthomyxoviridae (8 segments), Bu-
nyaviridae (3 segments), and Arenaviridae (2 segments).
These virus families include some of the world’s most
notorious pathogens, and methods for engineering at-
tenuated variants or recombinant viruses for vaccine
purposes have long been needed. In addition, many of
these viruses serve as important models for basic re-
search on all aspects of viral replication. Thus the recov-
ery of complete negative-stranded RNA viruses from
cloned cDNAs is among the most exciting breakthroughs
in RNA virology in the 1990s since it has opened the door
to directed engineering of the viral genomes and a de-
tailed understanding of the function of the viral genes
and their products.
Investigators studying influenza virus were able to
recover viruses incorporating engineered RNA segments
as early as 1989 and 1990 (Luytjes et al., 1989; Enami et
al., 1990). Although the method applied to influenza al-
lowed the first site-directed mutagenesis in negative-
stranded RNA viruses, complete recovery of influenza
virus from cDNAs has still not been achieved. Engineer-
ing of influenza virus was accomplished with an inge-
nious though cumbersome method involving reconstitu-
tion in vitro of ribonucleocapsids (RNPs) containing a
single negative-sense RNA segment (derived by in vitro
transcription from a DNA clone), the nucleoprotein, and
the three polymerase subunits. This RNP complex was
then transfected into cells infected with influenza helper
virus defective in the gene product corresponding to the
RNA segment provided. This system has proven effective
in generating influenza viruses that contain mutations in
or substitutions of six of the eight influenza A virus
segments and one of the influenza B virus segments
(reviewed in Palese et al., 1996). This system has not
been successful in the rescue of nonsegmented, nega-
tive stranded (NNS) RNA viruses since reproducible re-
constitution of infectious RNPs containing full-length ge-
nomes, all of which are greater than 11 kb in length, has
not yet been achieved.
Schnell et al. (1994) found a key to recovery of NNS
RNA viruses that had eluded the field for several years.
The method they described is as follows. Plasmids en-
coding the viral nucleocapsid protein (N) and the poly-
merase proteins (L and P) under the control of T7 pro-
moters were transfected into cells previously infected
with recombinant vaccinia virus expressing the T7 poly-
merase protein (vTF7–3). In addition to these plasmids, a
plasmid encoding a full-length antigenomic viral RNA
under the control of a T7 promoter at the 59 end and a
self-cleaving ribozyme at the 39 end was also transfected
into the cells (Fig. 1). After transcription of RNAs from the
T7 promoters and translation of the encoded proteins,
nucleocapsid proteins assemble around the antigenomic
RNAs, and polymerase proteins then replicate these
RNPs to form RNPs containing genomic RNAs. After
transcription of mRNA from the genomic RNP and trans-
lation, infectious virus is assembled. This procedure led
to successful recovery of recombinant rabies virus, but
only from approximately 1 of 107 transfected cells.
The use of the positive sense antigenome RNA, rather
than the negative sense genome, was critical because of
an antisense problem. If the negative sense genome is
used instead, mRNAs encoding viral proteins can hybrid-
ize to the naked genomic RNA and prevent the critical
assembly of the genome into the RNP, the template for
transcription and replication (M. Whitt and J. Rose, un-
published data). The negative-strand viruses always
keep their genome in RNP form, probably in part to avoid
this antisense problem. When one starts with the posi-
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tive-strand antigenome, this RNA can form an RNP with-
out any interference from the mRNAs. Once in RNP form,
the positive strand can then be replicated to form full-
length minus strand RNPs that are wrapped into RNPs as
nascent RNA chains and thus immune to interference
from mRNAs.
The recovery of rabies by Schnell et al., reported in the
September, 1994 EMBO Journal, was also a key presen-
tation at the Ninth International Conference of Negative
Stranded RNA Viruses in Estoril, Portugal in October,
1994. Many researchers returned to their labs from this
meeting sensing that they too might obtain recoveries in
their own system by starting with the antigenomic RNA.
The initial success in rabies virus was indeed followed
by several successful recoveries in other NNS viral sys-
tems (Fig. 2) and by one application of the methodology
in the segmented, negative sense RNA viruses. In 1995
using a very similar strategy, Lawson et al. reported the
first successful recoveries of vesicular stomatitis virus
(VSV) from cDNAs. This paper described recoveries that
were obtained independently in the laboratories of
J. Rose and M. Whitt. Three months later a third group
reported recovery of VSV from cDNAs using the same
system (Whelan et al., 1995).
Application of the system within viruses of the Rhab-
doviridae family was just the beginning. In December
1995 there were three reports of recovery of viruses from
the Paramyxoviridae family of viruses. Radecke et al.
reported recovery of measles virus (a morbillivirus); Col-
lins et al. reported successful application to human re-
spiratory syncytial virus (RSV, a pneumovirus); and Gar-
cin et al. reported success with Sendai virus (a
paramyxovirus). Although variations within the recovery
systems were employed, each group found successful
recovery of progeny viruses dependent upon expression
of the viral positive-sense, antigenomic RNAs. Radecke
et al. employed a vaccinia-free system in which the
measles virus (MV) N and P proteins along with the T7
RNA polymerase were stably coexpressed in a 293 cell
line. Upon transfection of this cell line with plasmids
encoding the MV L protein and MV antigenomic RNA,
progeny MV were recovered at rates similar to those
reported by Schnell et al. and Lawson et al. Collins et al.
found coexpression of an additional RSV protein,
M2(ORF1), a transcriptional elongation factor, necessary
for recovery of RSV in a vaccinia MVA-T7 system.
In June of 1996, Kato et al. provided the second report
of recovery of Sendai virus from cDNAs. In this report,
virus was recovered from both negative and positive
sense RNAs transcribed in vivo in the vaccinia T7 sys-
tem, or transfected into the system after being tran-
scribed in vitro. The efficiency of recoveries from antige-
nomic RNA constructs was much higher than reported by
Garcin et al. The authors attribute this to: (1) truncation of
the T7 promoter (by removing the guanosine triplet) thus
providing a precise 59 end to the viral RNA transcripts, (2)
optimization of the NP, P, and L plasmid ratios, and (3)
inhibition of vaccinia cytopathic effect by incubating in
the presence of both ara C and rifampicin. Although the
FIG. 2. Chronology of recoveries for complete, infectious, negative-
strand RNA viruses from plasmid DNAs. Numbers in parentheses
indicate the first or second reports of recoveries for the same virus.
FIG. 1. Recovery of negative stranded RNA viruses from plasmid
DNAs. A typical procedure for recovery is shown. Cells are infected
with a vaccinia virus recombinant encoding the T7 RNA polymerase
and then transfected with plasmids encoding the full-length viral anti-
genome and three plasmids encoding the viral nucleocapsid (N) and
polymerase proteins (P and L). The antigenome assembles into a
nucleocapsid that is replicated to a genomic nucleocapsid. Subse-
quent transcription, translation, and virus assembly lead to release of
infectious virus particles.
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investigators were successful in recovering virus from
genomic RNA constructs, the efficiency of recoveries
was considerably lower (at least 100-fold) than recover-
ies from the positive RNA constructs.
Although 1996 proved to be a slower year in recovery
of new NNS RNA viruses, another success story
emerged. Bridgen and Elliott (1996) reported the first
recovery of a segmented RNA virus, the Bunyamwera
virus, solely from cDNAs. In contrast to the influenza
system, which required helper virus, a helper-free sys-
tem based on the NNS RNA virus recovery systems was
employed. Bunyamwera virus, the prototype of the Bun-
yaviridae viruses, has a trisegmented genome. There-
fore, Bridgen and Elliott transfected three plasmids ex-
pressing the three antigenomic viral segments (L, M, and
S) along with three T7-plasmids expressing the viral
mRNAs encoding all the viral proteins (N, NSs, G1, G2,
NSm, and L) into cells infected with the recombinant
vaccinia T7 virus. Each antigenomic RNA construct was
expressed from a T7 promoter and had the self-cleaving
HDV ribozyme at the 39 end. Each antigenome transcript
contained two extra nonviral guanosine residues at the
59 end. Bridgen and Elliott also reported a low efficiency
of recovery as might be expected from such a complex
system.
In 1997 three more viruses from the Paramyxoviridae
family were recovered from cDNA clones using either the
original vaccinia T7 expression system or the MVA-T7
system. Use of MVA, a vaccinia virus deficient in repli-
cation in many mammalian cells, alleviates the need for
purification of recovered viruses from contaminating vac-
cinia viruses when the recoveries are passaged in mam-
malian cells. In February 1997, Baron and Barrett re-
ported the successful recovery of another morbillivirus,
rinderpest virus (RPV) using the MVA-T7 system. In June
1997, Hoffman and Banerjee reported the recovery of
human parainfluenza virus type 3 (HPIV-3), another
paramyxovirus, and in September an independent group
also reported recovery of HPIV-3 (Durbin et al., 1997).
Hoffman and Banerjee used the vaccinia T7 system first
described by Schnell et al., whereas Durbin et al. used
the MVA-T7 system. Durbin et al. reported recovery of
HPIV-3 from both genomic and antigenome constructs
and thus is the second group to report successful recov-
ery from the genomic constructs. In October, the first
successful recovery of a rubulavirus, simian virus 5
(SV5), from cDNAs was reported using the MVA-T7 sys-
tem (He et al., 1997).
Although a complete recovery of influenza virus from
DNA has still not been achieved, a plasmid-based sys-
tem for the expression of influenza RNPs was reported
(Pleschka et al., 1996). The plasmid-based system was
modified to allow the nuclear expression of the influenza
RNAs. Expression of the RNA segment of interest was
under the control of a truncated pol I promoter at the 59
end and a self-cleaving ribozyme sequence at the 39 end.
The RNP protein components (PB1, PB2, PA, and NP)
were encoded on plasmids under the control of pol II
promoters (Pleschka et al., 1996). These plasmids were
transfected into cells and the RNPs assembled intracel-
lularly. No RNA transcript purification, no protein purifi-
cation, and no in vitro reconstitution of biologically active
RNPs were necessary. Although this system still neces-
sitates the use of influenza helper virus, it is a step in the
direction of a less cumbersome recovery system for
recombinant influenza viruses.
The earliest application of reverse genetics for VSV
demonstrated the ability to engineer recombinant vi-
ruses substituting the glycoprotein gene from a different
serotype (New Jersey) for the endogenous glycoprotein
gene (Indiana) (Lawson et al., 1995). In 1996, subsequent
reports demonstrated that additional genes could be
added to the viral genomes. The bacterial chloramphen-
icol acetyl transferase (CAT) gene was expressed as an
extra gene in VSV (Schnell et al., 1996b) and in rabies
virus (Mebatsion et al., 1996). CAT gene expression in
recombinant VSVs was shown to be dependent only on
insertion of additional transcriptional start and stop sig-
nals, which are present within the nearly conserved 23
nucleotide sequence found at each VSV gene junction.
CAT expression was quite stable because it was main-
tained in cells infected with recombinant VSV-CAT even
after many low multiplicity passages. Subsequent re-
ports described CAT expression in recombinant RSV
(Bukreyev et al., 1996), luciferase expression in recom-
binant Sendai virus (Hasan et al., 1997), and expression
of the green fluorescent protein (GFP) in recombinant
SV5 (He et al., 1997).
In the NNS RNA viruses, the construction of viral
genomes expressing foreign genes is dependent upon
the addition of the foreign gene and the appropriate
transcription start and stop signals recognized by the
viral polymerase. The level of expression of the foreign
gene is dependent upon the location within the genome;
the closer the gene is to the initial transcription start at
the 39 end, the greater the expression. The expression
level of the bacterial CAT gene as a function of position
is illustrated in Fig. 3. The levels of expression obtained
are consistent with a well-documented transcription at-
tenuation of ;30% occurring at each gene junction (Iver-
son and Rose, 1981).
In recombinant VSVs it has been shown that the ad-
dition of foreign genes results in bullet-shaped progeny
virions longer than the wild-type VSV virions (Schnell et
al., 1996a; Kretzschmar et al., 1997). The additional length
of the particles reflects the additional genome length
contributed by the insert. Multiple genes, adding up to
4.2 kb of RNA, have been introduced into recombinant
VSVs and the helical nucleocapsids grow longer to ac-
commodate the 38% increase in RNA length (J. Forman,
K. Haglund, and J. Rose, unpublished data). In some
recombinants, the viral titers and budding efficiencies
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are reduced when compared with wild-type VSV. The
reduced titers appear to be due to a variety of factors
including the length of the insert, the level of the foreign
protein expression, and inhibition of the viral life cycle by
some foreign proteins. Although an upper limit for the
size of recombinant VSV genomes has not yet been
reached, one would expect the efficiency of replication
and budding to decrease with longer genomes to the
point where recovery will not be achieved.
CAT, luciferase, and GFP recombinants demonstrated
the ability to express foreign genes in NNS RNA virus
genomes. It has also been possible to generate recom-
binants expressing foreign membrane proteins, which
are incorporated into progeny virions. Indeed, the incor-
poration of foreign plasma membrane proteins into VSV
is remarkably permissive. Our group has shown expres-
sion and incorporation of the influenza A virus hemag-
glutinin (HA) and neuraminidase (NA) proteins (Kretz-
schmar et al., 1997), the HIV-1 envelope protein (gp160)
with a VSV-G cytoplasmic tail (Johnson et al., 1997), the
MV fusion (F) and hemagglutinin (H) proteins (Schnell et
al., 1996a), the RSV glycoprotein (G) and fusion (F) pro-
tein (J. Kahn, M. Schnell, L. Buonocore, and J. Rose,
unpublished data), and the cellular proteins CD4, CXCR4,
and CCR5 (Schnell et al., 1996a, 1997; E. Boritz, M.
Schnell, L. Buonocore, and J. Rose, unpublished data). In
all cases examined to date except for HIV envelope
protein, incorporation of the foreign proteins into the VSV
envelope does not require addition of the VSV G cyto-
plasmic tail. The potential of such recombinants in vac-
cine applications include the recent demonstration of the
recombinant VSV-HA as a highly effective intranasal vac-
cine. After a single dose VSV-HA completely protects
mice from lethal influenza virus challenge (Roberts et al.,
1998).
Genes encoding foreign membrane glycoproteins can
either be incorporated as extra genes in VSV or can be
incorporated in place of the VSV G gene (Schnell et al.,
1996a, 1997). By swapping the endogenous VSV G gene
for genes encoding foreign glycoproteins, it is possible
to obtain viruses containing the foreign proteins in their
envelopes. These viruses lack the normally broad tro-
pism conferred by VSV G and can be targeted to specific
cells. We use the term ‘‘surrogate viruses’’ for such novel
viruses. This term distinguishes them from pseudotypes,
which do not encode their foreign envelope proteins but
instead incorporate proteins expressed in trans. For ex-
ample, VSV recombinants expressing the HIV receptor
and a coreceptor in place of G incorporate both foreign
proteins and are targeted specifically to cells infected
with HIV-1 which display the HIV-1 envelope proteins on
their surface (Schnell et al., 1997). Further applications of
surrogate viruses in which VSV G is eliminated (DG) may
permit reuse of the VSVDG vector for multiple vaccina-
tions with multiple antigens because the neutralizing
antibody response to VSV G will be eliminated.
Other applications of reverse genetics to NNS RNA
viruses have included the elimination of alternative gene
products encoded in the P genes (C and V proteins) to
evaluate their role in viral replication and pathogenesis.
Recombinant viruses deleting the VSV C and C9 proteins
(Kretzschmar et al., 1996), Sendai virus V protein (Kato et
FIG. 3. Gene expression levels at different sites in the VSV genome. VSV vectors allowing foreign gene expression at the indicated sites in the
genome were constructed by introducing the appropriate transcription start-stop signals flanking sites for insertion of foreign genes. The expression
sites were introduced in the noncoding regions of the indicated intergenic junctions. The levels of CAT protein expression as percent of total cell
protein at 7 h after infection are indicated (Schnell et al., 1996b; M. Schnell, L. Buonocore and J. Rose, unpublished data). The levels of protein
expression obtained for different genes vary above and below those obtained for CAT depending on the gene being expressed.
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al., 1997), Sendai virus C/C9 proteins and C/C9/Y1/Y2
proteins (Kurotani et al., 1998), MV V protein (Schneider
et al., 1997), or MV C protein (Radecke et al., 1996) have
been generated. Little or no effect on viral replication
was observed with the VSV or measles mutants in tissue
culture although MV C2 recombinants did have a re-
duced plaque size. In contrast to VSV and MV mutants,
the Sendai virus mutants did have significant effects on
viral replication. The Sendai virus V2 mutants were ei-
ther unaffected in viral replication in tissue culture or
potentiated when compared with wild-type Sendai virus.
However, the Sendai virus V2 recombinants were
greatly attenuated in pathogenicity in a mouse model.
Although the V2 recombinant initially replicated at levels
comparable with the wild-type virus in mice, it was
cleared more rapidly. The Sendai virus C/C9 recombi-
nants were significantly attenuated in viral replication in
tissue culture and were less pathogenic in mice than the
V2 recombinant. The Sendai virus C/C9/Y1/Y2 recombi-
nants were further attenuated in tissue culture growing
to even lower titers than the C/C92 recombinants.
Plasmid-based systems for generating recombinants
in the Rhabdoviridae, Paramyxoviridae, and Bunyaviridae
have unlocked the great potential of these systems and
applications are just beginning. It is feasible that intra-
cellular plasmid-based systems can be applied to the
remaining families of the segmented and nonsegmented
negative-stranded RNA viruses (Filoviridae, Orthomyxo-
viridae, and Arenaviridae). The expression of influenza
virus genomic RNAs from plasmids would need modifi-
cation for nuclear expression as described by Pleshka et
al. (1996) leaving still the challenge of efficient transfec-
tion of 12 plasmids (eight RNA segments and four RNP
components) into a single cell for a single recovery
event. Further challenges may also remain within viruses
that contain ambisense coding strategies (e.g., arenavi-
ruses, hantaviruses, and tospoviruses) before successful
recoveries in these viral systems become a reality.
Reverse genetic systems have opened the door to the
negative-strand RNA viruses and the technology is mov-
ing the field in many new directions. Viral attenuation
through specific mutations has obvious practical signif-
icance in vaccine development. Such attenuating muta-
tions include those eliminating gene products that are
nonessential for replication in tissue culture, those rear-
ranging gene order, and those deleting the cytoplasmic
tails of viral glycoproteins (Jin et al., 1996; Kato et al.,
1997; Kurotani et al., 1998; Roberts et al., 1998; Wertz et
al., 1998). Deletion mutants generally cannot revert, thus
permanent attenuation should be possible in such re-
combinants. Continuing genetic manipulations of the
NNS RNA viral genomes will allow determination of the
roles of numerous gene products whose functions were
not previously accessible.
Now that we can insert foreign genes into NNS viruses
and completely change the viral envelope, we can ad-
dress the potential of surrogate viruses as multiuse vac-
cines and antiviral vectors. Applications of targeted NNS
RNA viruses to specific killing of cancer cells should be
possible by incorporating the appropriate antibodies and
membrane fusion proteins into the viral envelope. How-
ever, controlling the host immune response to the vector
itself will be a major obstacle to practical application.
Surrogate viruses will also likely serve as tools for the
identification of new viral receptors for those viruses that
cannot be safely or efficiently grown in tissue culture.
Such potential is illustrated by a VSV lacking the G gene
pseudotyped with the Ebola virus glycoprotein, VSVDG/
Ebola-G pseudotypes (Takada et al., 1997).
We still need a clearer understanding of the interac-
tions determining efficient budding of the NNS RNA vi-
ruses. In VSV, specific interactions of glycoprotein tails
with internal virion components have only small effects
on virus budding (Schnell et al., 1998), yet the VSV G
protein dramatically enhances virus budding. Identifica-
tion of a minimal VSV G domain enhancing budding
could be very important to future design of targeted VSV
vectors that bud more efficiently. Detailed exploration of
complex problems such as assembly are now possible
with the advent of modern genetics to the negative-
strand virus field.
ACKNOWLEDGMENTS
Dr. Anjeanette Roberts is supported by a Cancer Research Institute
Fellowship. We thank Karl Haglund for helpful comments on this review.
REFERENCES
Baron, M. D., and Barrett, T. (1997). Rescue of rinderpest virus from
cloned cDNA. J. Virol. 71(2), 1265–1271.
Bridgen, A., and Elliott, R. M. (1996). Rescue of a segmented negative-
strand RNA virus entirely from cloned complementary DNAs. Proc.
Natl. Acad. Sci. USA 93(26), 15400–15404.
Bukreyev, A., Camargo, E., and Collins, P. L. (1996). Recovery of infec-
tious respiratory syncytial virus expressing an additional, foreign
gene. J. Virol. 70(10), 6634–6641.
Collins, P. L., Hill, M. G., Camargo, E., Grosfeld, H., Chanock, R. M., and
Murphy, B. R. (1995). Production of infectious human respiratory
syncytial virus from cloned cDNA confirms an essential role for the
transcription elongation factor from the 59 proximal open reading
frame of the M2 mRNA in gene expression and provides a capability
for vaccine development. Proc. Natl. Acad. Sci. USA 92(25), 11563–
11567.
Durbin, A. P., Hall, S. L., Siew, J. W., Whitehead, S. S., Collins, P. L., and
Murphy, B. R. (1997). Recovery of infectious human parainfluenza
virus type 3 from cDNA. Virology 235(2), 323–332.
Enami, M., Luytjes, W., Krystal, M., and Palese, P. (1990). Introduction of
site-specific mutations into the genome of influenza virus. Proc. Natl.
Acad. Sci. USA 87(10), 3802–3805.
Garcin, D., Pelet, T., Calain, P., Roux, L., Curran, J., and Kolakofsky, D.
(1995). A highly recombinogenic system for the recovery of infectious
Sendai paramyxovirus from cDNA: Generation of a novel copy-back
nondefective interfering virus. EMBO J. 14(24), 6087–6094.
Hasan, M. K., Kato, A., Shioda, T., Sakai, Y., Yu, D., and Nagai, Y. (1997).
Creation of an infectious recombinant Sendai virus expressing the
firefly luciferase gene from the 39 proximal first locus. J. Gen .Virol.
78(11), 2813–2820.
5MINIREVIEW
He, B., Paterson, R. G., Ward, C. D., and Lamb, R. A. (1997). Recovery of
infectious SV5 from cloned DNA and expression of a foreign gene.
Virology 237(2), 249–260.
Hoffman, M. A., and Banerjee, A. K. (1997). An infectious clone of human
parainfluenza virus type 3. J. Virol 71(6), 4272–4277.
Iverson, L. E., and Rose, J. K. (1981). Localized attenuation and discon-
tinuous synthesis during vesicular stomatitis virus transcription. Cell
23(2), 477–484.
Jin, H., Subbarao, K., Bagai, S., Leser, G. P., Murphy, B. R., and Lamb,
R. A. (1996). Palmitylation of the influenza virus hemagglutinin (H3) is
not essential for virus assembly or infectivity. J. Virol. 70(3), 1406–
1414.
Johnson, J. E., Schnell, M. J., Buonocore, L., and Rose, J. K. (1997).
Specific targeting to CD41 cells of recombinant vesicular stomatitis
viruses encoding human immunodeficiency virus envelope proteins.
J. Virol. 71(7), 5060–5068.
Kato, A., Sakai, Y., Shioda, T., Kondo, T., Nakanishi, M., and Nagai, Y.
(1996). Initiation of Sendai virus multiplication from transfected cDNA
or RNA with negative or positive sense. Genes Cells 1(6), 569–579.
Kato, A., Kiyotani, K., Sakai, Y., Yoshida, T., and Nagai, Y. (1997). The
paramyxovirus, Sendai virus, V protein encodes a luxury function
required for viral pathogenesis. EMBO J. 16(3), 578–587.
Kretzschmar, E., Buonocore, L., Schnell, M. J., and Rose, J. K. (1997).
High-efficiency incorporation of functional influenza virus glycopro-
teins into recombinant vesicular stomatitis viruses. J .Virol. 71(8),
5982–5989.
Kretzschmar, E., Peluso, R., Schnell, M. J., Whitt, M. A., and Rose, J. K.
(1996). Normal replication of vesicular stomatitis virus without C
proteins. Virology 216(2), 309–316.
Kurotani, A., Kiyotani, K., Kato, A., Shioda, T., Sakai, Y., Mizumoto, K.,
Yoshida, T., and Nagai, Y. (1998). Sendai virus C proteins are cate-
gorically nonessential gene products but silencing their expression
impairs viral replication and pathogenesis. Genes Cells 3(2), 111–
124.
Lawson, N. D., Stillman, E. A., Whitt, M. A., and Rose, J. K. (1995).
Recombinant vesicular stomatitis viruses from DNA [published Erra-
tum appears in Proc Natl Acad Sci USA 92(19), 9009]. Proc. Natl.
Acad. Sci. USA 92(10), 4477–4481.
Luytjes, W., Krystal, M., Enami, M., Pavin, J. D., and Palese, P. (1989).
Amplification, expression, and packaging of foreign gene by influ-
enza virus. Cell 59(6), 1107–1113.
Mebatsion, T., Schnell, M. J., Cox, J. H., Finke, S., and Conzelmann, K. K.
(1996). Highly stable expression of a foreign gene from rabies virus
vectors. Proc. Natl. Acad. Sci. USA 93(14), 7310–7314.
Palese, P., Zheng, H., Engelhardt, O. G., Pleschka, S., and Garcia-
Sastre, A. (1996). Negative-strand RNA viruses: Genetic engineering
and applications. Proc. Natl. Acad. Sci. USA 93(21), 11354–11358.
Pleschka, S., Jaskunas, R., Engelhardt, O. G., Zurcher, T., Palese, P., and
Garcia-Sastre, A. (1996). A plasmid-based reverse genetics system
for influenza A virus. J. Virol. 70(6), 4188–4192.
Radecke, F., and Billeter, M. A. (1996). The nonstructural C protein is not
essential for multiplication of Edmonston B strain measles virus in
cultured cells. Virology 217(1), 418–421.
Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch,
C., Christiansen, G., and Billeter, M. A. (1995). Rescue of measles
viruses from cloned DNA. EMBO J. 14(23), 5773–5784.
Roberts, A., Kretzschmar, E., Perkins, A. S., Forman, J., Price, R., Buono-
core, L., Kawaoka, Y., and Rose, J. K. (1998). Vaccination with a
recombinant vesicular stomatitis virus expressing an influenza virus
hemagglutinin provides complete protection from influenza virus
challenge. J. Virol. 72(6), 4704–4471.
Schnell, M. J., Buonocore, L., Boritz, E., Ghosh, H. P., Chernish, R., and
Rose, J. K. (1998). Requirement for a non-specific glycoprotein cyto-
plasmic domain sequence to drive efficient budding of vesicular
stomatitis virus. EMBO J. 17(5), 1289–1296.
Schnell, M. J., Buonocore, L., Kretzschmar, E., Johnson, E., and Rose,
J. K. (1996a). Foreign glycoproteins expressed from recombinant
vesicular stomatitis viruses are incorporated efficiently into virus
particles. Proc. Natl. Acad. Sci. USA 93(21), 11359–11365.
Schnell, M. J., Buonocore, L., Whitt, M. A., and Rose, J. K. (1996b). The
minimal conserved transcription stop-start signal promotes stable
expression of a foreign gene in vesicular stomatitis virus. J. Virol.
70(4), 2318–2323.
Schnell, M. J., Johnson, J. E., Buonocore, L., and Rose, J. K. (1997).
Construction of a novel virus that targets HIV-1-infected cells and
controls HIV-1 infection. Cell 90(5), 849–857.
Schneider, H., Kaelin, K., and Billeter, M. A. (1997). Recombinant mea-
sles viruses defective for RNA editing and V protein synthesis are
viable in cultured cells. Virology 227(2), 314–322.
Schnell, M. J., Mebatsion, T., and Conzelmann, K. K. (1994). Infectious
rabies viruses from cloned cDNA. EMBO J. 13(18), 4195–4203.
Takada, A., Robison, C., Goto, H., Sanchez, A., Murti, K. G., Whitt, M. A.,
and Kawaoka, Y. (1997). A system for functional analysis of Ebola
virus glycoprotein. Proc. Natl. Acad. Sci. USA 94(26), 14764–14769.
Wertz, G. W., Perepelista, V. P., and Ball, L. A. (1998). Gene rearrange-
ment attenuates expression and lethality of a nonsegmented nega-
tive strand RNA virus. Proc. Natl. Acad. Sci. USA 95(7), 3501–3506.
Whelan, S. P., Ball, L. A., Barr, J. N., and Wertz, G. T. (1995). Efficient
recovery of infectious vesicular stomatitis virus entirely from cDNA
clones. Proc. Natl. Acad. Sci. USA 92(18), 8388–8392.
Yu, D., Shioda, T., Kato, A., Hasan, M. K., Sakai, Y., and Nagai, Y. (1997).
Sendai virus-based expression of HIV-1 gp120: reinforcement by the
V(-) version. Genes Cells 2(7), 457–466.
6 MINIREVIEW
